New Market Report: Poland Pharmaceuticals & Healthcare Report Q2 2015

The Polish pharmaceutical market is heavily dependent on public healthcare spending; any negative economic developments will have an impact on the market in the short term. Over the past five years, Poland's economic outperformance has been vital to maintaining positive growth for the private and public healthcare sectors. While Poland's economy may continue to outperform in terms of growth, we believe that overall healthcare spending will remain muted over the coming year given the bleak macroeconomic outlook for Central and Eastern Europe. We highlight this as an ongoing risk to our projections, but maintain our current outlook for this sector's growth over 2015.

Headline Expenditure Projections

Full Report Details at
- http://www.fastmr.com/prod/956900_poland_pharmaceuticals_healthcare_report_q2_2015.aspx?afid=301

* Pharmaceuticals: PLN33.68bn (USD10.75bn) in 2014 to PLN35.73bn (USD10.68bn) in 2015; +6.1% in local currency terms and -0.6% in US dollar terms.
* Healthcare: PLN115.15bn (USD36.74bn) in 2014 to PLN120.75bn (USD36.11bn) in 2015; +4.9% in local currency terms and -1.7% in US dollar terms.

Risk/Reward Index

Poland has a RRI score of 61.5 out of 100, making it 2nd the most attractive pharmaceutical market in Central and Eastern Europe, overtaken by the Czech Republic (63.2).

Key Trends And Developments

December 2014

The board of Poland-based healthcare group EMC Instytut Medyczny is discussing whether to acquire or operate several local government hospitals, and expects to finalise at least one to three deals in 2015, reports local newspaper Puls Biznesu, citing CEO Agnieszka Szpara. EMC is mainly targeting district hospitals, as it has expertise in managing such facilities, and also seeks to acquire complementary services in a given area. The group plans to invest between PLN5-PLN6mn (USD1.49-USD1.79mn) to modernise its hospital in Kwidzyn, Poland, which was acquired in 2013. The company has invested more than PLN100mn (USD29.86mn) in its acquired hospitals' infrastructure over the last decade and has similar expenditure plans for the next ten years.

<em...</em...<>

The Poland Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Poland Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Poland pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Poland, to test other views - a key input for successful budgeting and strategic business planning in the Polish pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bulgaria Pharmaceuticals & Healthcare Report Q2 2015
- South Korea Pharmaceuticals & Healthcare Report Q2 2015
- Peru Pharmaceuticals & Healthcare Report Q2 2015
- Nigeria Pharmaceuticals & Healthcare Report Q2 2015
- Mexico Pharmaceuticals & Healthcare Report Q2 2015